Clinical Trial Update: Nebulized Fentanyl for Respiratory Symptoms in Patients With COVID-19 [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating nebulized fentanyl for respiratory symptoms in COVID-19 pneumonia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Pneumonia

Drugs mentioned

• Nebulized fentanyl (fentanyl)

Snippet

Sponsor: Hamad Medical Corporation | Conditions: COVID-19 Pneumonia | Phase 3 | Status: UNKNOWN